Sagimet Biosciences Inc.

SGMT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001400118

Price chart

Open-market purchases and sales by SGMT insiders, newest first.

Insider trades
Filed (ET)Trade dateInsiderTransactionSharesAvg priceValueShares afterHolding changeFiling
Aug 17, 20264:05 PM ETAug 14, 2026Kemble GeorgeDirectorSSaleSeries A Common Stock−350.99K$10.2328−$3.59M62.16K−85.0%SEC10b5-1
Aug 12, 20267:41 PM ETAug 11, 2026Kemble GeorgeDirectorSSaleSeries A Common Stock−20.21K$9.9548−$201.15K62.16K−24.5%SEC10b5-1
Jul 22, 20264:05 PM ETJul 20, 2026Happel DavidPresident & CEOSSaleSeries A Common Stock−64.05K$7.7605−$497.07K741.57K−8.0%SEC
Jul 22, 20264:05 PM ETJul 20, 2026Rozek ElizabethChief Legal & Admin. OfficerSSaleSeries A Common Stock−10.55K$7.7603−$81.83K224.41K−4.5%SEC
Jul 22, 20264:05 PM ETJul 20, 2026Kemble GeorgeDirectorSSaleSeries A Common Stock−18.84K$7.4575−$140.53K62.16K−23.3%SEC10b5-1

The largest institutional positions in SGMT at the end of Q2 2026.

Institutions holding SGMT in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
BlackRock, Inc.6,575,788$50.83M0.00%+5,775,845+722.0%Added
Balyasny Asset Management LLC3,626,113$28.03M0.05%+3,626,113New
Woodline Partners LP3,000,652$23.2M0.07%+1,999,709+199.8%Added
SILVERARC CAPITAL MANAGEMENT, LLC2,927,698$22.63M2.52%+2,927,698New
VANGUARD CAPITAL MANAGEMENT LLC2,566,272$19.84M0.00%+1,467,353+133.5%Added